RPG Life Sciences Ltd (RPGLIFE) is currently trading at 2,590.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

RPG Life Sciences is an integrated pharmaceutical company manufacturing and marketing domestic formulations, international formulations, APIs, and intermediates across chronic, specialty, and selected acute therapies. It operates five manufacturing facilities, serves more than 63 countries, reaches over one lakh doctors and 3,000 stockists in India, and generates most revenue from domestic formulations. The strongest near-term growth engine is the API business, whose Q2 FY27 sales rose 89.2% year-on-year and H1 sales increased 58.5%. The acceleration reflects expanded manufacturing capabilities and acquired businesses, although the segment still represented only 13% of Q2 revenue, leaving substantial execution and integration work ahead. Domestic Formulations delivered 13% H1 growth, 1.2 times the Indian Pharma Market, while the company improved its market ranking from 62 to 50 between March 2025 and September 2026. Naprosyn crossing ₹100 crore in secondary sales demonstrates that legacy brands can still produce meaningful growth when supported by lifecycle management and focused commercial execution. RPG Life Sciences is combining pharmaceutical expansion with digital transformation, including AI-enabled physician engagement, GenAI commercial dashboards, IoT-supported plant monitoring, and electronic quality systems. These initiatives may improve productivity, compliance, and customer reach, but the presentation does not quantify their direct revenue contribution or savings. The company’s market capitalisation rose 64% during H1 FY27 to ₹5,023 crore, substantially outperforming the Sensex and BSE Healthcare Index. However, the presentation also highlights a P/E above 40 versus peer benchmarks near 23–25, indicating that continued growth, successful acquisitions, and sustained margins are already important to valuation expectations.

Over the past 52 weeks, RPG Life Sciences Ltd has traded between a low of ₹1,731.25 and a high of ₹3,130.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

RPG Life Sciences Ltd has a market capitalization of approximately 4,304.03. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

RPG Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 38.77 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,304.03 Cr, RPG Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

RPG Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of RPG Life Sciences Ltd is 38.77. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

RPG Life Sciences reported consolidated Q2 FY27 revenue of Rs 211.64 crore.

The transfer was completed and became effective on August 15, 2026, according to the company’s letter to NSE and BSE.

Revenue from operations was ₹195.7 crore in Q1FY27, up from ₹168.9 crore in Q1FY26, a year-on-year increase of 15.8%.

Revenue from operations rose to ₹195.7 crore in Q1FY27, up from ₹168.9 crore in Q1FY26.